Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in December

Coya Therapeutics, Inc. (NASDAQ:COYA) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 209,200 shares, an increase of 10.2% from the December 15th total of 189,800 shares. Currently, 1.4% of the shares of the company are short sold. Based on an average daily volume of 92,500 shares, the days-to-cover ratio is currently 2.3 days.

Insider Activity at Coya Therapeutics

In related news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of $7.34 per share, with a total value of $36,700.00. Following the purchase, the chief executive officer now directly owns 5,000 shares in the company, valued at approximately $36,700. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders bought a total of 9,510 shares of company stock valued at $69,615 in the last three months. 12.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new position in Coya Therapeutics in the 2nd quarter valued at approximately $101,000. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics in the 3rd quarter valued at approximately $169,000. Finally, Geode Capital Management LLC grew its holdings in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after buying an additional 4,485 shares during the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Price Performance

Shares of COYA stock traded down $0.22 during trading hours on Friday, reaching $5.38. 63,988 shares of the company’s stock were exchanged, compared to its average volume of 51,707. The company has a market cap of $89.88 million, a P/E ratio of -8.28 and a beta of 0.46. The company’s 50 day moving average is $6.02 and its two-hundred day moving average is $6.49. Coya Therapeutics has a 1 year low of $4.75 and a 1 year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. As a group, analysts predict that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Analysts Set New Price Targets

COYA has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, November 11th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, December 18th.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.